Introduction
Brand name: Asteceteam 500
Manufacturer: Astemax Biotech Pvt. Ltd.
Composition: Levetiracetam 500 mg tablet
Overview
Asteceteam 500 is an antiepileptic medication containing levetiracetam 500 mg per tablet, used for the management of partial‑onset seizures with or without secondary generalisation in adults and adolescents (≥12 years, usually ≥50 kg). It can be used as monotherapy or adjunctive therapy in combination with other antiepileptic drugs (AEDs).
Key features
Mechanism: Levetiracetam is a pyrrolidone‑derivative AED that binds to the synaptic vesicle protein SV2A, modulating neurotransmitter release and reducing neuronal hyperexcitability without affecting major ion channels or GABA‑glutamate systems.
Pharmacokinetics: It has linear pharmacokinetics, high oral bioavailability, low plasma‑protein binding, and is mainly excreted unchanged via the kidneys, allowing straightforward dose adjustments in renal impairment.
Precautions
Use cautiously in patients with renal impairment, history of psychiatric illness (e.g., depression, aggression, suicidal ideation), or prior seizure‑worsening with other AEDs.
Asteceteam 500 can be positioned as a WHO‑GMP‑oriented, broad‑spectrum antiepileptic tablet for neurologists and physicians managing partial‑onset seizures and other approved seizure types under updated national guidelines.
